Background-In a prospective, nonrandomized, consecutive series of tibioperoneal vessel angioplasty (TPVA), critical limb ischemia (CLI) patients' data were analyzed with regard to immediate and follow-up success. Methods and Results-TPVA was successful in 270 of 284 critically ischemic limbs (95%), with 167 limbs (59%) requiring dilatation of 333 ipsilateral inflow obstructions to access and successfully dilate 486 of 529 (92%) tibioperoneal lesions. A clinical success (relief of rest pain or improvement of lower-extremity blood flow) was attained in 270 limbs at risk (95%). Clinical 5-year follow-up of 215 of 221 successful CLI patients (97%) with 266 successfully revascularized limbs revealed that bypass surgery occurred in 8% and significant amputations in 9% of limbs; 91% of the limbs were salvaged. The cohort's probability of survival was 56%: 58% for Fontaine class III and 33% for class IV patients. Class III compared with class IV patients had significantly (PϽ0.05) fewer surgical bypasses (3% versus 16%) and amputations: above-knee, 1% versus 4%; below-knee, 3% versus 12%; and transmetatarsal, Ͻ1% versus 21%. Conclusions-TPVA, often in combination with inflow lesions, is an effective primary treatment for critical limb ischemia.
A ngioplasty of the tibioperoneal vessels has had limited application as a primary revascularization strategy for patients with critical limb ischemia (CLI), [1] [2] [3] [4] with the rationale of its limitation focusing on the requirement for revascularization of inflow lesions and the doubtful success of emergency surgery. [5] [6] [7] The need for emergency surgery after tibioperoneal vessel angioplasty (TPVA), however, appears to be overstated. 8 This communication details the acute outcome of 235 CLI patients with 284 ischemic limbs who, often after ipsilateral inflow lesion balloon angioplasty, underwent balloon angioplasty of infrapopliteal tibioperoneal vessel outflow lesions. The 5-year follow-up of 215 of 221 successful CLI patients (97%) and 266 successfully revascularized limbs delineated the occurrence of surgical bypass, amputation, and survival.
Methods
CLI patients with angiographic infrapopliteal arterial occlusive disease with or without concomitant inflow disease, amenable to angioplasty, were eligible for participation in this trial. Angiograms were performed in the majority of patients before the interventional procedure. With technique improvements, however, angiograms were performed just before the intervention; occasionally, the inter-ventions needed required staged procedures. Between 1983 and 1996, the nurse coordinator prospectively collected data on the consecutive patients who underwent angioplasty to improve lowerextremity arterial circulation. Amenable angioplasty targets included short, discrete lesions, diffuse stenotic lesions, and occlusions: within the superficial femoral and popliteal arteries of Ͻ35 cm and for tibioperoneal vessels of Ͻ10 cm with distal vessel visualization. Patient evaluation and interventional techniques have been published. 8 Clinical follow-up was obtained through periodic outpatient visits, direct phone call assessments, and correspondence with the primary physician, with attention directed to the presence of ischemic rest pain, resolution of the ischemic tissue injuries, amputation, and causes of death. Ankle-brachial indexes (ABIs) and plethysmography were not performed in patients with obvious advanced ischemic disease.
CLI Definitions
CLI was defined as (1) persistent, recurring rest pain requiring analgesia, and an ankle systolic pressure Յ50 mm Hg, and/or toe systolic pressure Յ30 mm Hg, and/or (2) ulceration, gangrene, or nonhealing wounds of the foot with ankle systolic pressure Յ50 mm Hg or toe systolic pressure Յ30 mm Hg. The Fontaine classification 9 stratified patients as class III (rest pain) or class IV (ulceration and/or gangrene).
Results
Patient demographic data are presented in Table 1 . Proximal inflow arterial occlusive disease was often necessary (59% of ischemic limbs) to permit access to diseased infrapopliteal vessels ( Table 2) . Dilatation was successful in all 337 inflow lesions and in 486 of 529 infrapopliteal lesions (92%): 370 of 376 stenoses (98%) and 116 of 153 occlusions (73%) ( Table  3) . Complications (Table 4 ) encountered included 20 episodes of transient contrast-induced acute renal failure (7%), 3 emergency vascular surgeries (0.7%), 1 procedurally related death (0.4%), 1 amputation after popliteal-tibial bypass (0.4%), and 1 compartment syndrome (0.4%). At hospital discharge, 221 patients demonstrated clinical improvement (Table 5) , with success attained in 165 of 166 class III limbs (99%) and 105 of 118 class IV limbs (90%).
Clinical 5-year follow-up on 215 of 221 CLI patients (97%) ( Table 6 ) with 266 successfully revascularized limbs revealed that, by use of a hierarchical stratification, bypass surgery occurred in 8% and significant amputation in 9% of limbs. The probability of survival of the cohort (Figure 1 ) was 56%: 58% for class III and 33% for class IV patients ( Figure  2 ). Class III compared with class IV patients had significantly (PϽ0.05) fewer surgical bypasses (3% versus 16%) and amputations: above-knee 1% versus 4%, below-knee 3% versus 12%, and transmetatarsal Ͻ1% versus 21%. Thus, salvage was attained in 91% of ischemic limbs. The eventfree 5-year survival (freedom from death and any repeat vascular procedures) was 31% for the entire cohort (class III, 43% versus class IV, 26%; PϽ0.05).
Discussion
The definition, pathophysiology, clinical presentation, and sequelae of CLI all may seem intuitively obvious. For these TPVA data to have meaning in attempts to assess their place next to historical data, however, requires an appreciation of the various definitions and their distinctions so as to provide a frame of reference.
CLI Definitions
Although the definitions of CLI vary within the surgical literature, they all are relatively consistent with the definitions used here. The International Vascular Symposium Working Party 10 defined severe rest pain as that which required opiate analgesia for Ն4 weeks, and either ankle pressure Ͻ40 mm Hg or ankle pressure Ͻ60 mm Hg in the presence of tissue necrosis or digital gangrene. The Modified International Vascular Symposium Working Party 11 defined severe rest pain as that which required opiate analgesia for Ն4 weeks and either an ankle pressure Ͻ40 mm Hg or tissue necrosis or Iliofemoral indicates common iliac, external iliac, and common femoral arteries; SFA-popliteal, superficial femoral and popliteal arteries; and TPV (ipsilateral), tibioperoneal vessels on the same side (ipsilateral) as the iliofemoral or SFA-popliteal lesions. digital gangrene. The First European Working Group 12 defined severe rest pain as that requiring opiate analgesia for Ն2 weeks, or ulceration or gangrene, or ankle pressures Ͻ50 mm Hg. The Second European Consensus Document 13 defined persistently recurring ischemic rest pain as that which required analgesia for Ͼ2 weeks and an ankle systolic pressure Ͻ50 mm Hg, and/or a toe systolic pressure Ͻ30 mm Hg, or ulceration or gangrene of the foot or toes and an ankle systolic pressure Ͻ50 mm Hg, or toe systolic pressure Ͻ30 mm Hg.
Surgical Approaches
Femoropopliteal arterial reconstruction for infrainguinal peripheral arterial occlusive disease has better immediate and long-term results in patients with claudication than in those with CLI, 14 and elective bypass surgery to the distal tibial vessels for intermittent claudication has had poor results. Thus, tibial artery bypass surgery to achieve revascularization distal to infrapopliteal obstructions has been reserved for selected CLI patients except in the presence of lifethreatening sepsis (until resolved), 15 flexion contractures or paralysis, 16 patients with serious comorbid medical conditions, or patients with markedly reduced life expectancy. Although data on distal bypasses have not been encouraging, Veith and colleagues [5] [6] [7] 17 improved their distal bypass results by using innovative and creative techniques, which resulted in a dramatic decrease in their procedure-related amputation rates (49% to 14%). Their distal bypass procedures, however, had a coincident 30-day mortality of 4% and 90-day graft failure rates of nearly 5%. These data became the standard of care, with success defined as clinical improvement with resolution of rest pain. Yet, the problems of worsening graft patency as a result of distal anastomoses to small diseased vessels, diffuse distal arterial occlusive disease producing poor runoff (outflow), grafts crossing a joint, or graft composition (vein versus synthetic material) 7,18 -20 make the use of percutaneous interventions even more attractive.
Curiously, not all patients whose first graft occluded required a second operation. Interestingly, the limb did not usually become rethreatened despite the original graft occlusion, and the wound did not recur after having healed. Such observations could be interpreted as indicating "surgical failure." If the therapeutic aim were to have a patent vessel, however, then graft closures would represent failure, but if the goal were to relieve rest pain or enable wound healing, then despite graft closure the procedure was successful. If this observation were extended to angioplasty, then lesion recurrence or restenosis might not be a major issue if the rest pain were no longer present or wound healing had occurred.
Surgical Results
Published longitudinal surgical data provided perspective to the usefulness of these TPVA data; 5 series will be detailed to show the similarities between the surgical and angioplasty data. A 2-year follow-up by the Italian census office of 522 CLI patients (394 men, 76%) 21 detailed demographics of hypertension in 303 (58%), diabetes mellitus in 157 (30%), previous revascularization procedures in 113 (22%), prior myocardial infarction in 98 (19%), previous strokes in 54 (10%), and a lower limb amputation (30 [6%] major and 22
[4%] minor) in 52 (10%). Presenting symptoms included intermittent claudication in 449 patients (86%), rest pain in 200 (38%), and ischemic ulcers or gangrene in 322 (62%). This cohort's ABI revealed that 4% had an ABI Ͼ0.75; 6% an ABI 0.51 to 0.75; 61% an ABI 0.25 to 0.50; and 22% an ABI Ͻ0. 25 . Thus, the ABI was often not specific to severe ischemia. In the hospital, 232 patients (44%) had a revascularization procedure and 49 (10%) amputation (30 [6%] 22 3-year follow-up of 275 patients (116 women [51%]; mean age 72 years) with severe lower-limb ischemia involving 275 ischemic limbs revealed that rest pain was the clinical presentation in 168 limbs (61%), ulceration in 56 (20%), and gangrene in 51 (19%). Bilateral occlusive severe peripheral vascular disease was common, with 25 patients (11%) having had a previous contralateral limb amputation. The recorded ABIs were Ͻ0.40 in 158 patients (66%), Ͻ0.50 in 183 (74%), but Ն0.50 in 62 (26%), which again confirms the lack of specificity of the ABI. The therapeutic strategies included arterial reconstruction in 235 limbs (86%), primary amputation in 19 (7%), digital amputation in 6 (2%), and conservative management of 15 (6%). During the 3-year follow-up period, 100 patients (27 primary and 101 after a failed reconstruction or sympathectomy). The operative mortality rates were significant: 5% for reconstruction or sympathectomy and 15% for major amputation. Survival probabilities were 80% at 1 year, 50% at 5 years, and 35% at 10 years. The 2-year survival rates correlated with the surgical procedure: 70% for arterial reconstruction, 60% for sympathectomy, and 55% for major amputation.
Wolfe and Wyatt's 24 collation of 20 lower-leg ischemia publications on 6118 patients stratified these patients into a low-risk cohort (4089 patients) (rest pain and ankle pressure Ͼ40 mm Hg) and a high-risk cohort (2029 patients) (rest pain and tissue loss [with or without ankle pressure Ͻ40 mm Hg]). The cumulative probability of survival for the entire group was 74% at 1 year, 58% at 2 years, 56% at 3 years, 48% at 4 years, and 44% for 5 years. At 1 year, if conservative treatments were used, 73% of the low-risk patients and 95% of the high-risk patients had lost their limb. When arterial reconstruction was performed on this high-risk group, the outcome resulted in a major amputation in 25%, and 26% of this group would be dead no matter what the treatment.
Finally, a 69-site European registry 25 followed up 574 patients (431 men, 75%; mean age 71 years), of whom 485 (87.5%) had rest pain and 352 (64%) had ulcers or gangrene. Surgical management included arterial reconstruction in 195 (34%) and sympathectomy in 55 (10%); a major amputation was necessary in 53 patients (9%), a minor amputation in 30 patients (5%), thromboendarterectomy in 44 (8%), angioplasty in 41 (7%), and epidural spinal electrostimulation in 22 (4%) . At the 3-month follow-up, 50 patients had died (9%), and 286 patients (50%) were alive, had no ischemic limb, and had not endured any major cardiovascular event; 103 patients (18%) were alive but had persistent CLI, 70 patients (12%) were alive but had endured a major amputation, and 9 patients (2%) were alive but had suffered an infarction or stroke and still had persistent limb ischemia. Thus, surgical reconstruction can be achieved in patients with CLI, but at the cost of significant morbidity and mortality.
Angioplasty Results
These TPVA data demonstrate revascularization success rates (94%) similar if not superior to those in recent publications. 26 -31 These studies must be looked at carefully, however, because the definitions of CLI were often indistinct. Not unexpectedly, TPV disease was often (59% of limbs) preceded by inflow lesion angioplasty so as to gain access to the obstructed tibioperoneal vessels. The patients of Lofberg et al 31 required this approach in 55 of 94 procedures (59%). The successful inflow lesion angioplasty markedly improved the distal perfusion pressure (as would be attained by femoropopliteal bypass), but in addition, the distal perfusion pressure to the ischemic foot was enhanced by angioplasty of the outflow lesion, not readily achieved with surgery. At 5-year follow-up, 91% of limbs were salvaged, which is significantly higher than and in sharp contrast to those reported, because follow-up extended for 2 years (89%, 26 49%, 27 80%, 28 87% 29 ), and rarely 3 years (87%, 26 72% 28 ). The 5-year survival statistics were sobering, with only a 56% survival; and these values were supported by the 76% 2-year 26 and the 75% 3-year 29 survivals. These TPVA data, with similar patient demographics, and the impressive procedural success demonstrate that this interventional technique is an important therapeutic option. The TPVA procedural and follow-up results were superior to those of the historical surgical series; the differences in endovascular and surgical survival rates, however, are even more dramatic when the surgical procedural operative mortality is considered. Endovascular procedures offer a significant alternative to surgical procedures.
Conclusions
Endovascular therapy has an important and definitive role for patients with infrapopliteal arterial occlusive disease and CLI by easily revascularizing inflow and outflow lesions with minimal morbidity and mortality, which significantly improved distal extremity perfusion pressure. This more complete restoration of blood flow than can be attained by bypass surgery in the presence of the outflow lesions resulted in immediate relief of rest pain and enhancement of wound healing, often in conjunction with transmetatarsal amputation. TPVA produced improved patient outcomes, and the 5-year follow-up data showed that the need for subsequent surgical bypass or amputation was acceptable considering the patient populations. Although the survival statistics were sobering, they direct us toward the need for much more aggressive diagnostic and therapeutic approaches for these patients. These patients have advanced, diffuse coronary heart and/or cerebrovascular disease. This issue requires our immediate attention. This communication raises other issues that must be addressed: is stent-supported angioplasty with or without adjunctive use of glycoprotein inhibitors superior to balloon angioplasty? Does brachytherapy have a therapeutic role, especially with regard to restenosis? These data, however, provide evidence that angioplasty is the primary therapy for patients with CLI.
